Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2132 Survival and Prognosis in Patients with Duodeno-Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an inherited syndrome, affecting multiple endocrine glands. Duodeno-pancreatic neuroendocrine tumors (DP-NET) represent the most frequent type of NET in MEN1. Their prognosis and treatment strategy is debated.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Modica R

Authors: Modica R, Lo Calzo F, De Cicco F, Bottiglieri F, Sciammarella C,

Keywords: neuroendocrine tumor, MEN1 syndrome, duodeno pancreatic tumor.,

#1770 Cytokines as Predictive Factors of Response to Somatostatin Analogues in Patients with Neuroendocrine Tumour

Introduction: The somatostatin analogues are a major therapeutic advance in neuroendocrine tumor (NET) treatment and have multiple modulatory effects on the immune system.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Sciammarella C

Authors: Sciammarella C, Grimaldi A, Circelli L, Modica R, Pizza G,

Keywords: cytokines, neuroendocrine, cell,

#1758 Efficacy and Safety of Low Dose Vandetanib in Metastatic Medullary Thyroid Cancer

Introduction: Medullary thyroid cancer (MTC) is an aggressive thyroid malignancy. Vandetanib is a tyrosine kinase inhibitor approved for locally advanced or metastatic MTC, administered orally 300 mg/daily. Diarrhea, hypertension and QT prolongation are common side effects and may require withdrawal or dose reduction.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Modica R

Authors: Modica R, Pizza G, Lo Calzo F, De Cicco F, Sciammarella C,

Keywords: medullary thyroid cancer, tyrosine kinase inhibitor,

#1756 Somatostatin Analogs in Patients with Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Efficacy and Safety

Introduction: Zollinger-Ellison syndrome (ZES) can cause severe complications. In multiple endocrine neoplasia type 1 (MEN1) related ZES, surgery has a controversial role and proton pump inhibitors (PPI) are usually first-line therapy, although some concerns regarding long-term use. Somatostatin analogs (SSA) both reduce hypergastrinemia and have an antiproliferative role.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Modica R

Authors: Modica R, Pizza G, Lo Calzo F, De Cicco F, Sciammarella C,

Keywords: somatostatin analogs, MEN1, Zollinger-Ellison syndrome,

#1109 Expression and Role of the CXCR4/CXCL12/CXCR7 Axis and Crosstalk with the mTOR Pathway in Neuroendocrine Tumors (NETs)

Introduction: Chemokine receptor CXCR4 has been shown to signal on mTOR pathway in gastric and renal cancer. CXCR4 interacts with the chemokine CXCL12 to exert proliferative and chemotactic effects.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Sciammarella C

Authors: Sciammarella C, Circelli L, Guadagno E, Tafuto S, Del Basso De Caro M,

Keywords: chemokine, mtor, nets, clinical outcome.,